Evidence map›Paper›PMID 41438067›Full record

ArticleiScience2025

The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.

Dongshan Chen, Zhen Li, Yapeng Sui, Yuan Zeng, Haochen Cui, Laiyuan Qiu, Lin Yang, Shuolei Li, Ziwei Wei, Siling Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dongshan ChenDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.
Zhen LiDepartment of Urology, Beijing Chaoyang Hospital Affiliated Capital Medical University, Beijing 100020, China.
Yapeng SuiDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.
Yuan ZengDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.
Haochen CuiDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.
Laiyuan QiuDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.
Lin YangDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.
Shuolei LiShandong Academy of Pharmaceutical Sciences, Shandong Engineering Research Center of New Sustained and Controlled Release Formulations and Drug Targeted Delivery Systems, Jinan 250014, China.
Ziwei WeiDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Siling ChenCollege of Pharmacy, Shandong First Medical University, Jinan 250117, China.
Cong ZhangDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.
Lei YanDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Re-transurethral resection of bladder tumors (reTURBTs) improves staging and local control in high-risk bladder cancer, posing the clinical challenge of determining the most effective adjuvant intravesical regimen. In this multicenter retrospective study, 174 patients undergoing reTURBT between 2010 and 2024 received either Bacillus Calmette-Guérin (BCG) or pirarubicin/epirubicin (THP/EPI) intravesical therapy, delivered as post-reTURBT instillations alone (PIT) or combined with interval instillations before and after reTURBT (IIT + PIT). We compared recurrence-free survival (RFS) and adverse events across regimens and performed subgroup analyses by tumor characteristics. IIT + PIT significantly prolonged RFS: BCG IIT + PIT conferred a 2.93-fold lower recurrence risk versus BCG PIT (

Indexed as

CancerTherapeutics

Identifiers

PMID41438067
PMCPMC12719213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.